18 Mar 2021
BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program
Author: admintech | Filed under: Press ReleaseVANCOUVER, BC, March 18, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into an agreement with Bioanalytical…